Close
Novotech
Jabsco PureFlo 21 Single Use

Elligo Health Research Launches Novel IntElligo Research Stack Clinical Technology

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.
- Advertisement -

Elligo Health Research, an integrated research organization (IRO), announces the launch of its innovative IntElligo Research Stack™ clinical technology.

This standards-based technology platform, which powers the System of Accelerated Research (SOAR™) model, will be launched this month as the eSource documentation tool at Elligo’s Research Ready network of study sites.

 ”IntElligo can be set up per the study protocol in hours and easily follows the workflow in any physician’s office,” said Jacylyn Bodmer, Elligo’s chief information officer. “We are improving data quality while relieving administrative burden at the research site and enabling more patient-centric interactions. IntElligo also facilitates remote monitoring, which results in faster source data verification and financial payments to our physicians.”                                                                                                                                  

“IntElligo bridges health care and research, leveraging global industry standards from the start (CDISC PRM and CDASH), thus facilitating aggregation and tabulation into CDISC SDTM, the required format for regulatory eSubmissions to the FDA and Japan’s PMDA,” added Rebecca Kush, Ph.D., Elligo’s chief scientific officer.

In addition, the technology provides real-time management financial management, reports, and analytics across research sites; saves time and preserves data integrity by eliminating transcription; and, achieves true eSource. Furthermore, it creates the opportunity to transform research through the SOAR™ model — expanding patient access and driving efficiency by enabling direct data from source to submission.  

“By uniting our Goes Direct® approach with this technology and infrastructure to support physicians, we are creating the ultimate solution for clinical trial execution,” said John Potthoff, Ph.D., Elligo CEO. “The IntElligo platform will become a primary resource for our study sites, increasing the ability for physicians to provide research as a care option and enabling more patients to benefit.” 

About Elligo
Elligo Health Research, an integrated research organization, accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using our novel IntElligo Research Stack™ clinical technology and our Goes Direct® approach. We unite the best clinical experts with the best research infrastructure — creating the ultimate clinical trial solution. By maintaining the integrity of the trusted patient and physician relationship and building global communities of research that leverage electronic health records, we ensure all patients have access to clinical trials as a care option. Learn more at elligodirect.com

Latest stories

Related stories

Smarter Trial Design Improves Drug Development Speed

Optimization of clinical trial protocols through innovative designs and strategic endpoint selection directly accelerates drug development speed and improves operational reliability.

Data Driven Decisions Improve Drug Development Outcomes

Integrating comprehensive analytics and real-world data into clinical planning allows pharmaceutical companies to optimize trial design and significantly improve patient outcomes.

Efficient Early Strategies Enable Faster Clinical Progress

Implementing optimized early-stage frameworks and enhancing trial readiness allows pharmaceutical sponsors to accelerate clinical timelines and maintain high R&D efficiency.

Early Insights Reduce Risk in Drug Development Programs

Leveraging early-stage data and translational research allows pharmaceutical companies to mitigate drug development risk and implement adaptive strategies for higher success.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »